Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Authors
Toomey, SineadEustace, Alexander J
Fay, Joanna
Sheehan, Katherine M
Carr, Aoife
Milewska, Malgorzata
Madden, Stephen F
Teiserskiene, Ausra
Kay, Elaine W
O'Donovan, Norma
Gallagher, William
Grogan, Liam
Breathnach, Oscar
Walshe, Janice
Kelly, Catherine
Moulton, Brian
Kennedy, M John
Gullo, Guiseppe
Hill, Arnold D
Power, Colm
Duke, Deirdre
Hambly, Niamh
Crown, John
Hennessy, Bryan T
Issue Date
2017-07-27Keywords
CANCERGENETICS
Local subject classification
BREAST CANCERMeSH
AdultAged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Carboplatin
Class I Phosphatidylinositol 3-Kinases
Female
Gene Expression Regulation, Neoplastic
Genotype
Humans
Middle Aged
Mutation
Neoadjuvant Therapy
PTEN Phosphohydrolase
Quinazolines
Receptor, ErbB-2
Signal Transduction
Taxoids
Trastuzumab
Metadata
Show full item recordCitation
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. 2017, 19 (1):87 Breast Cancer Res.Publisher
BioMed CentralJournal
Breast cancer research : BCRDOI
10.1186/s13058-017-0883-9PubMed ID
28750640Additional Links
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530949/Abstract
The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) in 19% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers. Because ERBB family mutations can activate the PI3K/AKT pathway and likely have similar canonical signalling effects to PI3K pathway mutations, we investigated their combined impact on response to neoadjuvant HER2-targeted therapies.Item Type
ArticleLanguage
enISSN
1465-542XSponsors
This work was supported by the Irish Cancer Society Collaborative Cancer Research Centre under BREAST-PREDICT grant CCRC13GAL (www.breastpredict.com), the Health Research Board (HRA/POR2012/054), the North East Cancer Research and Education Trust, and the Science Foundation Ireland-funded Molecular Therapeutics for Cancer Ireland (08-SRC-B1410)ae974a485f413a2113503eed53cd6c53
10.1186/s13058-017-0883-9
Scopus Count
Collections
Related articles
- Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
- Authors: Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R
- Issue date: 2018 Feb
- Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
- Authors: Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC
- Issue date: 2011 Jan 10
- Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
- Authors: Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Peña L, Ellis C, Eidtmann H, Piccart-Gebhart MJ, Scaltriti M, Baselga J
- Issue date: 2015 Jul
- Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
- Authors: Loibl S, Darb-Esfahani S, Huober J, Klimowicz A, Furlanetto J, Lederer B, Hartmann A, Eidtmann H, Pfitzner B, Fasching PA, Tiemann K, Jackisch C, Mehta K, von Minckwitz G, Untch M, Denkert C
- Issue date: 2016 Jun 1
- PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
- Authors: Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C
- Issue date: 2014 Oct 10